Surgical Science Sweden AB (publ) carries a market capitalization of 1.70B, placing it among publicly traded companies globally. Its enterprise value stands at 884.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1.70B |
| Enterprise Value | 884.60M |
Surgical Science Sweden AB (publ) currently has 51.03M shares outstanding.
| Shares Outstanding | 51.03M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Surgical Science Sweden AB (publ) trades at a trailing price-to-earnings ratio of 29.69. The price-to-sales ratio is 1.59, and the price-to-book ratio stands at 2.13.
| PE Ratio | 29.69 |
| PS Ratio | 1.59 |
| PB Ratio | 2.13 |
| P/TBV Ratio | 1.66 |
| P/FCF Ratio | 7.50 |
| P/OCF Ratio | 10.33 |
On an enterprise value basis, Surgical Science Sweden AB (publ) trades at an EV/EBITDA multiple of 13.03 and an EV/FCF ratio of 4.28. The EV/Sales ratio of 0.91 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 13.03 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.91 |
| EV / EBITDA | 13.03 |
| EV / EBIT | 13.03 |
| EV / FCF | 4.28 |
Surgical Science Sweden AB (publ) maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.44 |
| Quick Ratio | 2.50 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | 0.03 |
| Interest Coverage | N/A |
Surgical Science Sweden AB (publ) posts a return on equity of 7.44 and a return on invested capital of 1.05.
| Return on Equity (ROE) | 7.44 |
| Return on Assets (ROA) | 1.08 |
| Return on Invested Capital (ROIC) | 1.05 |
| Return on Capital Employed (ROCE) | 7.42 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.71 |
Over the trailing twelve months, Surgical Science Sweden AB (publ) has paid 23.35M in income taxes, reflecting an effective tax rate of 30.90.
| Income Tax | 23.35M |
| Effective Tax Rate | 30.90 |
Surgical Science Sweden AB (publ)'s stock has declined approximately -77.06813% over the past 52 weeks. The 50-day moving average sits at 33.58, while the 200-day moving average is 50.28.
| Beta (5Y) | N/A |
| 52-Week Price Change | -77.06813% |
| 50-Day Moving Average | 33.58 |
| 200-Day Moving Average | 50.28 |
| Average Volume (20 Days) | N/A |
Over the trailing twelve months, Surgical Science Sweden AB (publ) generated 977.13M in revenue and converted that into 52.21M in net income, yielding earnings per share of 1.02. EBITDA reached 67.88M, while operating income came in at 67.88M.
| Revenue | 977.13M |
| Gross Profit | 640.05M |
| Operating Income | 67.88M |
| Pretax Income | 75.56M |
| Net Income | 52.21M |
| EBITDA | 67.88M |
| EBIT | 67.88M |
| Earnings Per Share (EPS) | 1.02 |
Surgical Science Sweden AB (publ) holds 667.73M in cash and equivalents against 2.15M in total debt, resulting in a net debt position of -665.58M. Total book value stands at 727.41M, with working capital of 919.17M providing operational flexibility.
| Cash & Cash Equivalents | 667.73M |
| Total Debt | 2.15M |
| Net Debt | -665.58M |
| Equity (Book Value) | 727.41M |
| Book Value Per Share | 14.26 |
| Working Capital | 919.17M |
Surgical Science Sweden AB (publ) produced 150.05M in operating cash flow over the past twelve months. After subtracting -56.60M in capital expenditures, free cash flow totaled 93.45M - equivalent to 1.83 per share.
| Operating Cash Flow | 150.05M |
| Capital Expenditures | -56.60M |
| Free Cash Flow | 93.45M |
| FCF Per Share | 1.83 |
Surgical Science Sweden AB (publ) operates with a gross margin of 65.50, reflecting its pricing power and cost economics. The operating margin of 6.95 and net profit margin of 5.34 provide insight into operational efficiency.
| Gross Margin | 65.50 |
| Operating Margin | 6.95 |
| Pretax Margin | 7.73 |
| Profit Margin | 5.34 |
| EBITDA Margin | 6.95 |
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 1.88 |
| FCF Yield | 13.33 |
Surgical Science Sweden AB (publ)'s most recent stock split took place on May 25, 2020 with a 1:5 split ratio.
| Last Split Date | 5/25/2020 |
| Split Ratio | 1:5 |
Surgical Science Sweden AB (publ) posts an Altman Z-Score of 4.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.90 |